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TRPA1a b s t r a c t
Although feverfew has been used for centuries to treat pain and headaches and is recommended for
migraine treatment, the mechanism for its protective action remains unknown. Migraine is triggered
by calcitonin gene-related peptide (CGRP) release from trigeminal neurons. Peptidergic sensory neurons
express a series of transient receptor potential (TRP) channels, including the ankyrin 1 (TRPA1) channel.
Recent findings have identified agents either inhaled from the environment or produced endogenously
that are known to trigger migraine or cluster headache attacks, such as TRPA1 simulants. A major constit-
uent of feverfew, parthenolide, may interact with TRPA1 nucleophilic sites, suggesting that feverfew’s
antimigraine effect derives from its ability to target TRPA1. We found that parthenolide stimulates
recombinant (transfected cells) or natively expressed (rat/mouse trigeminal neurons) TRPA1, where it,
however, behaves as a partial agonist. Furthermore, in rodents, after initial stimulation, parthenolide
desensitizes the TRPA1 channel and renders peptidergic TRPA1-expressing nerve terminals unresponsive
to any stimulus. This effect of parthenolide abrogates nociceptive responses evoked by stimulation of
peripheral trigeminal endings. TRPA1 targeting and neuronal desensitization by parthenolide inhibits
CGRP release from trigeminal neurons and CGRP-mediated meningeal vasodilatation, evoked by either
TRPA1 agonists or other unspecific stimuli. TRPA1 partial agonism, together with desensitization and
nociceptor defunctionalization, ultimately resulting in inhibition of CGRP release within the trigemino-
vascular system, may contribute to the antimigraine effect of parthenolide.
 2013 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.1. Introduction supercritical CO from feverfew, for migraine prevention with aFeverfew (Tanacetum parthenium L.) has been used for centuries
as a remedy for pain, fever, and headaches [26]. Feverfew, alone or
in combination with other compounds, has been long evaluated as
a prophylactic agent for migraine [24,28,41]. Positive well-pow-
ered, randomized clinical trials [14,37] have led to the recommen-
dation of MIG-99, a relatively stable extract manufactured with2
level B of evidence [22]. More recently, 2 similar sublingually
administered products containing feverfew and ginger have been
tested successfully as an acute treatment for migraine attacks
[12,13]. However, the underlying mechanism of the antimigraine
action of feverfew remains unknown.
The major constituent of feverfew is the sesquiterpene lactone,
parthenolide (Fig. 1A), which has previously been found to exert
anti-inflammatory effects [38,44]. Parthenolide may interact with
nucleophilic sites of proteins via its a-methylene-c-lactone ring
and epoxide moiety [36,42]. This chemical property qualifies a
number of reactive molecules as agonists of the transient receptor
potential ankyrin 1 (TRPA1), which by covalent modification of
Fig. 1. Parthenolide (PTL) selectively activates the TRPA1 channel. (A) Chemical structure of PTL. (B) Representative traces and concentration-response curve (CRC) of
intracellular calcium mobilization evoked by PTL in HEK293 cells transfected with the cDNA of human TRPA1 (hTRPA1-HEK293; black line) or in untransfected-HEK293 cells
(HEK293; gray line). Calcium response evoked by PTL (50 lM) was abolished by the selective TRPA1 antagonist, HC-030031 (HC; 30 lM). (C) Representative traces, (D) pooled
data, and (E) CRC of intracellular calciummobilization evoked by PTL (black dots and line) or allyl isothiocyanate (AITC; gray dots and line) in cultured rat trigeminal ganglion
(TG) neurons. Calcium response induced by PTL was abolished by HC (30 lM) and was unaffected by the selective TRPV1 antagonist, capsazepine (CPZ; 10 lM) (D). (F, G)
Calcium response evoked by PTL (100 lM) or AITC (30 lM) in TG neurons from Trpa1+/+ (black line and columns) was absent in neurons from Trpa1/ mice (gray line and
columns). Responses to capsaicin (CPS; 0.1 lM) were unchanged. Veh is the vehicle of PTL. Each trace represents an average of at least 15 responsive cells/neurons; each point
or column represents mean ± SEM of n > 25 cells/neurons. Dash indicates combined vehicles of treatments. §§§P < .001 vs Veh, ⁄⁄⁄P < .001 vs PTL (ANOVA followed by
Bonferroni test). ##P < .01 vs Trpa1+/+ treated group (Student t test).
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uniquely stimulated by an unprecedented series of reactive exoge-
nous and endogenous molecules generated by oxidative stress
[1,6,7,29,47].
A subset of primary afferents characterized as capsaicin-sensi-
tive because they express the capsaicin receptor transient receptor
potential vanilloid 1 (TRPV1) are also enriched with TRPA1 chan-
nels and express and release the sensory neuropeptides substance
P (SP), neurokinin A (NKA), and calcitonin gene-related peptide
(CGRP) [10,23,43]. CGRP release within the trigeminovascular sys-
tem is now considered to play a key role in the genesis of migraine
headaches [16,21,35]. In general, endogenous agents that activate
receptors/channels on trigeminal neurons to release CGRP may
be considered migraine generators, whereas exogenous com-
pounds that prevent such activation may be considered potential
migraine medicines [31].
More recently, the role of TRPA1 in migraine pathophysiology
has been suggested by the observation that both the reactive a,b-
unsaturated aldehyde and TRPA1 agonist, acrolein [7], and one ma-
jor volatile component of the headache tree (U. californica) scent,
umbellulone, selectively target TRPA1 to produce a CGRP-depen-
dent meningeal vasodilatation [15,25,33], which is considered a
predictive migraine model. Thus, we hypothesized that partheno-
lide exerts its antimigraine effect via TRPA1 targeting.Here we found that parthenolide activates both recombinant
and neuronal TRPA1. However, parthenolide behaves as a TRPA1
partial agonist, and by targeting TRPA1 causes selective channel
desensitization and a nonselective defunctionalization of CGRP-
containing sensory neurons. These 3 peculiar features of partheno-
lide, ultimately resulting in the inhibition of CGRP release from
trigeminal neurons, may contribute to the antimigraine effect of
feverfew.2. Materials and methods
2.1. Animals
Animal experiments were carried out in conformity to the
European Communities Council (ECC) guidelines for animal care
procedures and the Italian legislation (DL 116/92) application of
the ECC directive 86/609/EEC. Studies were conducted under the
University of Florence research permits 143/2008-B and 204/
2012-B. Male C57BL/6 mice (Harlan Laboratories, Milan, Italy),
wild-type (Trpa1+/+) or TRPA1-deficient (Trpa1/) mice [7], or
Sprague-Dawley rats (male, Harlan Laboratories) were used. Ani-
mals were killed with intraperitoneal sodium pentobarbital
(200 mg/kg).
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Flowered aerial parts of feverfew [Tanacetum parthenium L.
Schultz Bip., 2 kg] were extracted with ethanol. Removal of the
solvent left a dark gum, which was partitioned between petroleum
ether (2 L) and methanol-water (9:1, 2 L). The defatted methanol
phase was evaporated, and the residue (37 g) was suspended in
petroleum ether-ethyl acetate 1:1, and purified by vacuum chro-
matography on neutral alumina (300 g), using petroleum ether-
ethyl acetate 1:1 as eluent. The fractions containing parthenolide
were pooled and evaporated, and the residue was triturated with
ether, with a yield of 6.94 g (0.35% on dried plant material) of a
white powder, identified by direct comparison with an authentic
sample of parthenolide available from a previous study [3].
2.3. Reagents
If not otherwise indicated, all reagents were from Sigma-Aldrich
(Milan, Italy). HC-030031 was synthesized as described [2]. Parthe-
nolide extracted powder was dissolved in 100% dimethyl sulfoxide
(DMSO) at the final concentration of 100 mM.
2.4. Cell culture and isolation of primary sensory neurons
Human embryonic kidney (HEK293) cells stably transfected
with the cDNA of human TRPV1 (hTRPV1-HEK293) or with the
cDNA of human TRPA1 (hTRPA1-HEK293) and naive HEK293 cells
(American Type Culture Collection, Manassas, VA) were cultured
as previously described [33]. A tetracycline-regulated system for
inducible expression of TRPA1 in Chinese hamster ovary (CHO)
cells transfected with the cDNA of the mouse TRPA1 (mTRPA1-
CHO) was used and cultured as previously reported [32]. Naive
CHO cells were used as control. HumanTRPA1 (hTRPA1-CHO)
wild-type or mutant 3C/K-Q (C619S, C639S, C663S, K708Q) cDNAs
[19] (1 lg/mL) were expressed in naive CHO cells using a polyethy-
lenimine transfection method (PEI, Sigma-Aldrich, Milan, Italy)
[4,45] and cultured as previously reported [19]. All cells were cul-
tured in an atmosphere of 95% air and 5% CO2 at 37C. Trigeminal
ganglia (TG) neurons from rats and Trpa1+/+ or Trpa1/ mice were
collected as previously reported [33] (for details see Supplemen-
tary methods).2.5. Calcium imaging experiments
Calcium fluorescence was measured in transfected and untrans-
fected HEK293 cells or in trigeminal ganglia neurons, as previously
reported [29,33]. Plated cells were loaded with Fura-2AM-ester
(5 lM; Alexis Biochemicals, Lausen, Switzerland) added to the buf-
fer solution (37C) containing the following (in mM): 2 CaCl2; 5.4
KCl; 0.4 MgSO4; 135 NaCl; 10 D-glucose; 10 4-(2-hydroxyethyl)-
1-piperazineethanesulfonic acid (HEPES), 0.1% bovine serum albu-
min at pH 7.4. After 40 minutes, cells were washed and transferred
to a chamber on the stage of a Nikon Eclipse TE2000U microscope
for the recording. Cells were excited alternatively at 340 nM and
380 nM to indicate relative intracellular calcium changes by the
Ratio340/380 recorded with a dynamic image analysis system (Labo-
ratory Automation 2.0; RCSoftware, Florence, Italy). Cells and neu-
rons were exposed to parthenolide (30 to 1000 lM), allyl
isothiocyanate (AITC, 30 lM), or their vehicles (1%, 0.3% DMSO,
respectively). Capsaicin (0.1 lM) was used to identify nociceptive
neurons. HC-030031 (30 lM), capsazepine (10 lM), or their
respective vehicles (3% and 0.1% DMSO) were used. Results are ex-
pressed as the percentage of increase of Ratio340/380 over the base-
line normalized to the maximum effect induced by ionomycin
(5 lM) added at the end of the experiment (% change in R340/380).2.6. Electrophysiological recordings
Electrophysiological recordings in the whole-cell mode were
performed in CHO-transfected cells as previously reported [32]
(for details see Supplementary methods). TRPA1-evoked currents
were detected upon cell superfusion with parthenolide (100 lM)
and AITC (50 to 100 lM).
2.7. Eye-wiping assay in mice
Conjunctival application of parthenolide (12.5-25-50 nmol,
5 lL) or its vehicle (5% DMSO) was used to induce an acute noci-
ceptive response in mice [33]. In other experiments, mice received
conjunctival AITC (20 nmol) or capsaicin (1 nmol) 40 minutes after
a single (4 mg/kg, intraperitoneal) or repeated (once per day for
5 days, 4 mg/kg, intragastric) parthenolide administration. Data
are expressed as number of eye movements after drug application.
2.8. Dural cannulation and behavior testing
Dural cannulation and behavioral studies were performed un-
der protocols approved by the Institutional Animal Care and Use
Committee of the University of Arizona and were in accordance
with policies and recommendations of the International Associa-
tion for the Study of Pain and the National Institutes of Health
guidelines for handling and use of laboratory animals. Rat dura
cannulation and cutaneous allodynia measurement were per-
formed as described [49]. AITC (10%, 10 lL), capsaicin (1 lM,
10 lL), or their vehicle (mineral oil) were injected through the can-
nula 40 minutes after parthenolide (4 mg/kg, intraperitoneal) or its
vehicle (4% DMSO in phosphate-buffered saline). Calibrated von
Frey filaments were applied to the midline of the forehead and to
the hind paw at 1-hour intervals after injection of the stimuli. Max-
imum filament strengths were 8g and 15g for the face and hind
paws, respectively. The withdrawal thresholds were determined
by the Dixon up–down method.2.9. CGRP-like immunoreactivity (LI) assay
For CGRP-LI outflow experiments, 0.4-mm slices of rodent tis-
sues (rat spinal cord, trigeminal ganglia and dura mater, and
mouse spinal cord) were superfused with an aerated (95% O2 and
5% CO2) Krebs solution with the following composition (in mM):
119 NaCl, 25 NaHCO3, 1.2 KH2PO4, 1.5 MgSO4, 2.5 CaCl2, 4.7 KCl,
11 D-glucose; maintained at 37C, containing 0.1% bovine serum
albumin, and to minimize peptide degradation, added with the
angiotensin-converting enzyme inhibitor captopril (1 lM) and
the neutral endopeptidase inhibitor phosphoramidon (1 lM). Tis-
sues were stimulated with parthenolide (10-30-100 lM) or its
vehicle (1% DMSO) dissolved in modified Krebs solution. Some tis-
sues were pre-exposed to capsaicin (10 lM, 20 minutes) or super-
fused with a calcium-free buffer containing EDTA (1 mM). Others
tissues were pretreated with HC-030031 (30 lM), capsazepine
(10 lM), or pre-exposed to parthenolide (300 lM, 30 minutes)
and then, after a prolonged washing, stimulated with parthenolide
(100 lM), AITC (100 lM), capsaicin (0.3 lM), or KCl (40 mM). Frac-
tions (4 mL) of superfusate were collected at 10-minute intervals
before, during, and after administration of stimulus and then freeze
dried, reconstituted with assay buffer, and analyzed for CGRP-LI by
using a commercial enzyme-linked immunosorbent assay kit (Ber-
tin Pharma, Montigny le Bretonneux, France). CGRP-LI was calcu-
lated by subtracting the mean prestimulus value from those
obtained during or after stimulation. Detection limits of the assays
were 5 pg/mL. Results are expressed as femtomoles of peptide per
gram of tissue. Stimuli did not cross-react with CGRP antiserum.
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Changes in rat middle meningeal artery blood flow were re-
corded with a laser Doppler flowmeter (Perimed Instruments,
Milan, Italy) following the procedure reported elsewhere [33].
Briefly, rats were anesthetized (sodium pentobarbital, 50 mg/kg,
intraperitoneal), the head fixed in a stereotaxic frame. A cranial
window (4  6 mm) was realized into the parietal bone to expose
the dura mater. The probe (needle type, tip diameter 0.8 mm) was
fixed near a branch of the middle meningeal artery (1 mm from the
dural outer layer). The window was filled with a modified syn-
thetic interstitial fluid containing (in mM): 135 NaCl; 5 KCl; 1
MgCl2; 5 CaCl2; 10 D-glucose, and 10 HEPES. Meningeal blood flow
was monitored for 30 minutes after administration of parthenolide
(4 mg/kg, intraperitoneal) or AITC (1 lmol/kg, intraperitoneal).
Meningeal blood flow also was measured after the administration
of acrolein (50 nmol, intranasal), ethanol (140 lL/kg, intravenous),
sodium nitroprusside (SNP, 1 mM/100 lL, topically to the dura sur-
face) or their vehicles 30 minutes after parthenolide (4 mg/kg,
intraperitoneal). Baseline flowwas calculated by the mean flow va-
lue measured during a 5-minute period prior to stimulus. The in-
crease in blood flow was calculated as percent change over the
baseline.
2.11. Statistical analysis
All values are the mean ± SEM. Statistical analyses were per-
formed by the unpaired Student t test or the 2-way or 1-way anal-
ysis of variance (ANOVA), followed by the post-hoc Bonferroni test,
or by the Newman–Keuls test. A value of P < .05 was considered
statistically significant.
3. Results
3.1. Parthenolide activates recombinant and native TRPA1
Parthenolide is known to react with nucleophiles, in particular
with cysteine thiol groups, via a Michael addition reaction
[42,48], a mechanism through which many compounds activate
TRPA1 [2,19,27,47]. To verify if parthenolide targets TRPA1, we ex-
posed hTRPA1-HEK293 cells to parthenolide, which produced a
concentration-dependent increase in intracellular calcium, indicat-
ing a stimulatory action. This effect of parthenolide was absent in
HEK293 untransfected cells (Fig. 1B). In addition, the calcium re-
sponse evoked by parthenolide was abolished by the selective
TRPA1 antagonist, HC-030031 [30] (Fig. 1B), and absent in
hTRPV1-HEK293 cells (data not shown). Next, we examined the ef-
fect of parthenolide in cultured rat TG neurons. Parthenolide in-
creased intracellular calcium, and the effect was concentration
dependent (Fig. 1E), and abrogated by HC-030031, but was unaf-
fected by the TRPV1 antagonist, capsazepine (Fig. 1C and D). Par-
thenolide, similarly to the selective TRPA1 agonist allyl
isothiocyanate (AITC), produced a measurable calcium response
in about 40% of TG neurons isolated from Trpa1+/+ mice, an effect
that was completely absent in TG neurons isolated from Trpa1/
mice (Fig. 1F and G). In contrast, calcium response to capsaicin
was unchanged in neurons from both Trpa1+/+ and Trpa1/ mice
(Fig. 1G). All together, these findings indicate selectivity of parthe-
nolide for the TRPA1 channel. Furthermore, in rat trigeminal neu-
rons parthenolide showed, in addition to a lower potency, a
much reduced efficacy (maximum response, Emax: 22% ± 2% of ion-
omycin percent, n = 30) than that of AITC (Emax: 58% ± 5% of iono-
mycin, n = 26, P < .001) (Fig. 1E), thus indicating that it behaves
as a low-potency partial agonist at the TRPA1 channel.
Whole-cell patch-clamp recordings in both hTRPA1-CHO and
mTRPA1-CHO transfected cells confirmed the data obtained withcalcium experiments, as extracellular application of parthenolide
induced a fast activation of both outward and inward currents,
which were blocked by the TRPA1 antagonist HC-030031 and were
absent in CHO untransfected cells (Fig. 2A and B and
Supplementary Fig. 1). To get better insight into the molecular
mechanism of the parthenolide and TRPA1 interaction, mutagene-
sis studies and desensitization studies were undertaken. hTRPA1
activation by electrophilic agonists is dependent on the presence
of 3 key cysteine (C619, C639, C663) and 1 lysine (K708) residues
[19,27]. Parthenolide activates the TRPA1 channel through this
mechanism, as it was inactive in CHO transfected with the mutant
and humanTRPA1 mutant (C619S, C639S, C663S, K708Q) cDNA
(3C/K-Q), whereas the nonelectrophilic TRPA1 agonist, menthol
[45], activated both mutant and wild-type channels (Fig. 2C). In
calcium-containing solutions, application of parthenolide or AITC
produced typical inward TRPA1 currents in mTRPA1-CHO cells, fol-
lowed by a rapid calcium-mediated inactivation. Under these con-
ditions, TRPA1 was refractory to stimulation with a second
application of parthenolide or AITC (Fig. 2D and Supplementary
Fig. 1).
3.2. Parthenolide activates trigeminal nociceptive behavior and
allodynia and causes desensitization
Next, to investigate whether parthenolide, via TRPA1 targeting,
affects the functioning of trigeminal nociceptors, we used the eye
wiping assay in mice [33]. Conjunctival parthenolide instillation
evoked in a concentration-dependent manner an acute nociceptive
behavior in C57/BL6 mice and Trpa1+/+ mice, whereas a negligible
effect, indistinguishable from the response produced by partheno-
lide vehicle, was observed in Trpa1/ mice (Fig. 3A and B). Of no-
tice, the response evoked by conjunctival instillation of AITC
(Fig. 3C) was markedly reduced after systemic administration of
parthenolide. AITC was given 40 minutes after 1 single dose of par-
thenolide (4 mg/kg, intraperitoneal), or 40 minutes after the last of
5 daily treatments with parthenolide (4 mg/kg, intragastric)
(Fig. 3D). In contrast, either acute or chronic parthenolide treat-
ment did not affect the eye wiping response evoked by instillation
of the TRPV1 agonist capsaicin (Fig. 3C and D). This finding indi-
cates selective desensitization by parthenolide of nociceptive
behaviors evoked by TRPA1-specific stimuli.
Prior studies have shown that exposure of the dura to TRPA1
agonists produces time-dependent and reversible cutaneous allo-
dynia of the face and hind paws, which has been proposed as a pre-
clinical rat behavioral model of migraine [15]. Thus, we evaluated
whether systemic pretreatment with parthenolide (4 mg/kg intra-
peritoneal, 40 minutes before dural stimulation) was able to atten-
uate migraine-related behaviors in rats due to dural TRPA1
activation [15]. The data of the areas-over-time effect curve show
significant allodynia after AITC stimulation compared to vehicle
(mineral oil). Systemic pretreatment with parthenolide (4 mg/kg
intraperitoneal, 40 minutes before dural stimulation), but not its
vehicle (4% DMSO, in phosphate-buffered saline), prevented the
development of the cutaneous allodynia of the rat face (Fig. 3E)
and hind paw (Supplementary Fig. 2) produced by dural applica-
tion of AITC. However, systemic pretreatment with parthenolide
did not alter the cutaneous allodynia evoked by the dural applica-
tion of capsaicin (Fig. 3E and Supplementary Fig. 2). Again, these
findings underline that parthenolide abrogates solely TRPA1-
dependent afferent pathways.
3.3. Parthenolide releases CGRP from primary afferents and causes
nonselective desensitization
There is evidence that TRPA1 is exclusively localized to pep-
tidergic primary sensory neurons [10,43]. Experiments described
Fig. 2. Parthenolide (PTL) elicits characteristic TRPA1 current and causes desensitization. (A) Representative time courses and (B) pooled data of whole-cell currents through
humanTRPA1-CHO (hTRPA1-CHO) transfected cells measured at membrane potential of +50 mV (black curve) and 50 mV (gray curve), activated by PTL (100 lM), followed
by a fast block by the TRPA1 antagonist, HC-030031 (HC; 30 lM). No response was observed in untransfected CHO cells (CHO). Each column represents mean ± SEM of n > 5
cells. §§§P < .001 vs Veh and ⁄⁄⁄P < .001 vs PTL (ANOVA followed by Bonferroni test). (C) Average values ± SEM (n = 5 cells) for increased currents (at +50 and 50 mV) evoked
by PTL (100 lM) through hTRPA1 wild-type (WT) and mutant (3C/K-Q;Mut) CHO transfected cells. Values are normalized to activation induced by menthol (30 lM). PTL does
not activate Mut, whereas menthol, which interacts with TRPA1 in a non covalent manner, does. #P < .05, ##P < .01 vs WT (Student t test). (D) Representative time course of
whole-cell currents through mouseTRPA1-CHO transfected cells measured at membrane potential of +50 mV (black curve) and 50 mV (gray curve) evoked by PTL (100 lM).
A second stimulation of TRPA1 by PTL (100 lM) or allyl isothiocyanate (AITC; 100 lM) failed to evoke any current.
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the ability of parthenolide to affect the release of CGRP from
both central and peripheral endings of primary sensory neurons,
several preparations were used. Parthenolide increased the
outflow of CGRP-LI from rat spinal cord slices (Fig. 4A), an
effect prevented by pre-exposure to a high concentration of
capsaicin [46] and in a calcium-free medium. The effect of par-
thenolide was abated by HC-030031 but was unaffected by
capsazepine (Fig. 4A). In addition, pre-exposure to an elevated
concentration of parthenolide prevented parthenolide-evoked
CGRP-LI release from rat spinal cord, indicating self-desensitiza-
tion (Fig. 4A). Similar results were obtained in slices of rat TG
(Fig. 4C) or dura mater (Fig. 4D). Exposure to parthenolide in-
creased CGRP-LI outflow from dorsal spinal cord slices obtained
from Trpa1+/+ mice, an effect that was completely absent in tis-
sues taken from Trpa1/ mice (Fig. 4B). Finally, pre-exposure toan elevated concentration of parthenolide abated the increase in
CGRP-LI outflow elicited in rat dura mater by either capsaicin
or a high K+ medium (Fig. 4E). Thus, parthenolide by targeting
TRPA1, after an initial activation, causes nonselective and
complete desensitization of CGRP release from trigeminal
neurons.
3.4. Parthenolide modulates changes in meningeal blood flow by TRP
stimulants
A large body of evidence has shown that stimulants of peptider-
gic trigeminal neurons in rodents cause, among various effects,
either extravasation of plasma proteins in the dura mater (an effect
mediated by the tachykinins SP and NKA) or vasodilatation of men-
ingeal arterial vessels (a response mediated by CGRP) [31]. How-
ever, although tachykinin-dependent neurogenic edema does not
Fig. 3. Parthenolide (PTL) activates trigeminal nociceptive behavior in rodents via TRPA1 activation and induces desensitization. (A) Ocular instillation of PTL in C57/BL6 mice
produced a dose-dependent eye wiping nociceptive response. (B) The response to PTL observed in Trpa1+/+ mice was completely absent in Trpa1/ mice. Values are
mean ± SEM of 5 mice. §§§P < .001 vs Veh (ANOVA followed by Bonferroni test). ###P < .001 vs PTL-Trpa1+/+ (Student t test). (C) The eye wiping response (assessed 40 minutes
after PTL) evoked by ocular instillation of allyl isothiocyanate (AITC; 20 nmol/5 lL), was reduced by intraperitoneal PTL pretreatment (4 mg/kg). PTL pretreatment did not
modify the effect induced by ocular instillation of capsaicin (CPS; 0.5 nmol/5 lL). (D) The eye wiping response evoked by ocular instillation of AITC (20 nmol, assessed
40 minutes after the last PTL administration) was reduced after repeated treatment with intragastric PTL (4 mg/kg, once per day for 5 days). Veh is the vehicle of AITC or CPS,
§§§P < .001 vs Veh; ⁄⁄P < .01 and ⁄⁄⁄P < .01 vs PTL pretreated group (ANOVA followed by Bonferroni). (E) Time course and (F) area over the time-effect curve (AOC; baseline to
5 hours) of the facial allodynia evoked by the application of AITC (10% in mineral oil, Min Oil) or CPS (10 lL) or their vehicle (Min Oil 100%) on rat dura. The generalized
allodynia induced by AITC, but not that evoked by topical application of CPS, was prevented by PTL (4 mg/kg, intraperitoneal, given 40 minutes before dural application). Veh
is the vehicle of systemic PTL. Data represent the mean ± SEM of 6 rats per group. §P < .05 vs Min Oil, ⁄⁄P < .05 vs PTL pretreated group. Data were analyzed among groups and
across time (baseline to 5 hours) by 2-factor ANOVA followed by the Newman–Keuls test.
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resulting neurogenic vasodilatation seems to represent a major
underlying migraine mechanism [20,21,35]. Thus, we wondered
whether parthenolide affects meningeal blood flow in rats.
Whereas administration of AITC (intraperitoneal, 1 lmol/kg) pro-
duced a TRPA1-dependent and CGRP-mediated increase in menin-
geal blood flow (data not shown), the maximum achievable dose of
parthenolide (4 mg/kg, intraperitoneal) was ineffective (Fig. 4F).
Parthenolide (4 mg/kg, intraperitoneal, 30 minutes before the
stimulus) inhibited the meningeal vasodilatation evoked by both
intranasal acrolein instillation, a response that has been previously
identified as produced by TRPA1 activation [25], and by intranasal
capsaicin or intravenous ethanol, responses that are both mediated
by TRPV1 stimulation [34]. Parthenolide did not affect meningeal
vasodilatation evoked by the direct vasodilator agent sodium
nitroprusside (Fig. 4F and G). Finally, pretreatment with HC-
030031 prevented the inhibitory effect of parthenolide on etha-
nol-evoked vasodilatation (Fig. 4F and G). Results suggest that
parthenolide produces desensitization of perivascular meningeal
sensory fibers, which mediate CGRP-dependent vasodilatation.Because the desensitizing effect of parthenolide is not exclusively
confined to TRPA1-agonists, but also to stimuli such as acrolein,
capsaicin, or ethanol, which act via TRPA1-independent pathways
[25,34], it is possible that parthenolide, via TRPA1 targeting, causes
nonselective defunctionalization of peptidergic sensory nerve
terminals.4. Discussion
The first novelty of the present study, supported by unequivocal
pharmacological and genetic findings, is that parthenolide targets
TRPA1. In particular, deletion of TRPA1 makes mouse neurons
unresponsive to parthenolide, and both genetic and pharmacolog-
ical evidence indicates that parthenolide activates the human
TRPA1 variant, suggesting that responses produced by partheno-
lide in rodents could also be reproduced in humans. Mutagenesis
studies of the human TRPA1 indicate that the loss of function of
the mutant channel enlists parthenolide into the larger series of
electrophilic and reactive molecules, which activate TRPA1 via
Fig. 4. Parthenolide via TRPA1 activation releases CGRP from and causes desensitization of rat primary sensory neurons. (A) Parthenolide (PTL) increased the calcitonin gene-
related peptide-like immunoreactivity (CGRP-LI) outflow from rat dorsal spinal cord slices in a concentration-dependent manner. Effect of PTL (100 lM) was abolished by
calcium removal (Ca2+-free), capsaicin desensitization (CPS-des), and the selective TRPA1 antagonist HC-030031 (HC; 30 lM), but not by the selective TRPV1 antagonist
capsazepine (CPZ; 10 lM). Pre-exposure to a high concentration of PTL (300 lM, 30 minutes; PTL-des) also abolished PTL-evoked CGRP release. (B) PTL increased CGRP-LI
outflow from spinal cord slices from Trpa1+/+ mice, but not from Trpa1/mice. PTL elicited a HC-sensitive CGRP-LI release from rat trigeminal ganglia (C) and dura mater (D).
(E) Exposure to a high concentration of PTL (300 lM, 30 minutes) abated CGRP-LI release evoked by allyl isothiocyanate (AITC; 100 lM), capsaicin (CPS; 0.3 lM), or KCl
(40 mM). Veh is the vehicle of PTL. Values are mean ± SEM of n = 4 experiments. Dash indicates combined vehicles of the treatments. §P < .05 and §§§P < .001 vs Veh; ⁄⁄⁄P < .001
vs PTL (ANOVA followed by Bonferroni test). #P < .05, ##P < .01, and ###P < .001 vs Trpa1+/+ or respective vehicle group (Student t test). (F) Representative traces and (G) pooled
data of the increases in dural blood flow evoked by intranasal acrolein (ACR, 50 nmol/50 lL), intravenous ethanol (EtOH, 140 lL/kg, intravenous) or dural application of
sodium nitroprusside (SNP; 10 mM/100 lL). PTL (4 mg/kg, intraperitoneal) treatment (middle panel and bar graph) significantly reduced responses to ACR and EtOH, but not
to SNP, and HC (100 mg/kg, intragastric) pretreatment (right hand panel and bar graph) prevented the inhibitory effect evoked by systemic PTL (HC-PTL) on EtOH-evoked
response. Veh is the vehicle of PTL. Values are mean ± SEM of n > 5 animals. #P < .05 vs Veh (Student t test). §P < .05 vs Veh (ANOVA followed by Bonferroni test).
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[19,47].
TRPA1 agonists, including acrolein [25] or umbellulone [8,33],
have been proposed to trigger migraine headache attacks via
their ability to activate TRPA1 and the ensuing release of CGRP
from perivascular trigeminal nerve endings. Therefore, the clini-
cal use of feverfew in the treatment of migraine headache ap-
pears somehow contradictory to the present observation that
parthenolide stimulates TRPA1 and releases CGRP. However,
the second important novelty of our study consists in the obser-
vation that parthenolide acts as a TRPA1 partial agonist, pro-duces selective channel desensitization, and causes
defunctionalization of TRPA1-expressing peptidergic neurons,
eg, renders nerve terminals unresponsive to a number of differ-
ent stimuli. A reduced Emax of parthenolide as compared to that
of AITC was observed in cultured TG neurons. This finding sug-
gests that parthenolide behaves as a partial agonist at the TRPA1
channel. In the presence of endogenously produced agonists,
such as reactive oxygen species [9,40], or their byproducts,
including 4-hydroxynonenal [47], oxononenal [45], or acrolein
[7], the partial agonist activity of parthenolide may result in
TRPA1 inhibition.
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tion derives from its ability to produce desensitization of both
afferent (nociceptive) and efferent (neuropeptide-mediated and lo-
cal) responses of primary sensory neurons. In vitro electrophysio-
logical and organ bath studies and in vivo functional experiments
showed that parthenolide pretreatment attenuates TRPA1-
mediated responses. In particular, after initial activation, partheno-
lide caused channel desensitization in TRPA1-CHO cells, which
quickly became unresponsive to a second application of partheno-
lide or AITC.
Differences between parthenolide-induced desensitization of
afferent and efferent responses seem to depend on the localization
of TRPA1 in specific subsets of primary sensory neurons. Studies
with TRPA1-deficient mice and pharmacological treatments identi-
fied the wiping response to parthenolide and AITC [33] as entirely
mediated by activation of TRPA1 expressed in TRPV1-positive
neurons. In the case of this purely afferent response, parthenolide
pretreatment selectively reduced the wiping response by TRPA1-
agonists (AITC or parthenolide), but not that by a TRPV1 agonist
(capsaicin) (Fig. 4). Similar results were obtained in experiments
of facial allodynia produced by AITC application to the rat dura,
an effect that was completely abated by parthenolide, which in
contrast did not affect the capsaicin-evoked response. Thus,
desensitization to parthenolide seems to be confined to nocicep-
tive responses solely initiated by TRPA1 activation.
A different scenario emerges from neuropeptide release studies
in which the efferent function [23] of sensory nerves was investi-
gated. Pre-exposure to parthenolide prevented not only the ability
of TRPA1 agonists (AITC or parthenolide) to release CGRP from dur-
al sensory nerve terminals, but also that of a TRPV1 agonist (capsa-
icin) as well as that induced by high K+, a nonspecific depolarizing
agent. The most parsimonious explanation for this finding is that
parthenolide causes complete defunctionalization of peptidergic
trigeminal nerve endings, which are no longer able to release CGRP
and SP/NKA in response to any stimulus. Capsaicin has long been
known to produce sensory neuron defunctionalization [23], and
this property represents the mechanistic basis for the clinical use
of topical capsaicin treatments. The present findings are consistent
with the notion that TRPA1 agonists, likewise capsaicin, cause
homologous and heterologous desensitization [39].
How can the ability of parthenolide, intimately linked to TRPA1
targeting, to produce selective desensitization of TRPA1-mediated
afferent responses and nonselective inhibition of neurogenic (neu-
ropeptide-mediated) responses be clarified? One possible explana-
tion derives from the coexistence of TRPA1 in peptidergic neurons.
Although the observation has not been always confirmed [5],
TRPA1 seems to colocalize predominantly with neuropeptides
(SP/NKA and CGRP) in a specific subset of nociceptive neurons,
whereas a substantial portion of TRPV1-positive neurons that re-
sponds to capsaicin is not peptidergic and does not express TRPA1
[10,43]. Due to its selective action at TRPA1, parthenolide desensi-
tizes TRPA1 and defunctionalizes exclusively the subset of TRPA1-
expressing neurons, which however encompasses the entire
peptidergic neuronal subpopulation. Thus, after exposure to par-
thenolide, peptidergic neurons are no longer able to release CGRP
upon exposure to any stimulus, whereas nonpeptidergic, TRPA1-
negative, and TRPV1-positive neurons may still produce nocicep-
tive responses when exposed to a variety of stimuli, including
capsaicin.
In agreement with this hypothesis, we found that
parthenolide pretreatment reduces CGRP-mediated meningeal
vasodilatation evoked by either intranasal acrolein, an entirely
TRPA1-dependent phenomenon [25], or by intravenous ethanol,
an entirely TRPV1-dependent response [34]. In addition, reversal
by HC-030031 of parthenolide-evoked inhibition of vasodilata-
tion induced by ethanol robustly supports the role of TRPA1 inthis phenomenon. Defunctionalization by parthenolide of
neuropeptide-mediated and TRPA1-dependent responses in
in vitro experiments was complete. However, in vivo menin-
geal vasodilatation experiments, most likely because of poor
drug pharmacokinetics, defunctionalization seems to be partial.
Poor ability of gaining adequate concentrations for channel acti-
vation at perivascular strigeminal endings and/or weak agonism
may also be the reasons why intraperitoneal injection of parthe-
nolide failed to produce any measurable meningeal
vasodilatation.
Parthenolide and related sesquiterpene lactones have been
shown, among other effects, to inhibit the activation of the proin-
flammatory transcription factor nuclear factor-jB (NF-jB), by dif-
ferent stimuli, such as phorbol esters, tumor necrosis factor-a, and
hydrogen peroxide [11,17]. These findings are of relevance in mi-
graine because the nitric oxide donor, glyceryl trinitrate, known
to provoke delayed migraine attacks when infused in migraineurs,
increased the expression of inducible nitric oxide synthase by an
NF-jB–dependent mechanism [38]. The observation that both
NF-jB activation and inducible nitric oxide synthase expression
were attenuated by parthenolide [38] suggested that the antimi-
graine action of parthenolide may depend on the inhibition of this
key proinflammatory pathway. The underlying pharmacokinetic
and/or pharmacodynamic mechanism responsible for the neuronal
defunctionalization of TRPA1-expressing neurons by parthenolide
remains to be elucidated. Nevertheless, this novel property of par-
thenolide may add up to previously described anti-inflammatory
actions of the compound [18,36,38] to account for the ability of
chronically or acutely administered feverfew to prevent migraine
attacks [12–14].Acknowledgments
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